Expert Interviews

Kelley Lauren Coffman, MD, on the Design of a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
January 16, 2021

The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the design of a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.

Satya Das, MD, MSCI, on the Design of a Study of PRRT in Patients With Well-Differentiated NETs
January 15, 2021

The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Scott Kopetz, MD, PhD, on the Results of the SWOG S1406 Trial
January 15, 2021

SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.